Myriad Genetics Unveils Roadmap for Precise MRD Assay Commercialization in Breast, Colorectal, Renal, Ovarian, and Endometrial Cancers

Myriad Genetics unveiled a commercialization roadmap for its Precise MRD assay, which detects circulating tumor DNA in cancer patients. The assay will be launched in breast cancer in March 2026, followed by colorectal and renal cancers later that year, and expanded to ovarian and endometrial cancers in 2027. Interim clinical studies have shown high sensitivity and predictive power for recurrence and treatment response in breast and colorectal cancers.